1. Home
  2. IDR vs EOLS Comparison

IDR vs EOLS Comparison

Compare IDR & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$35.77

Market Cap

378.0M

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.71

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
EOLS
Founded
1996
2012
Country
United States
United States
Employees
N/A
329
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
304.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
IDR
EOLS
Price
$35.77
$4.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$17.50
$18.80
AVG Volume (30 Days)
632.9K
1.5M
Earning Date
11-12-2025
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
52.70
N/A
EPS
0.73
N/A
Revenue
$35,424,313.00
$285,823,000.00
Revenue This Year
$55.62
$13.94
Revenue Next Year
$23.93
$14.53
P/E Ratio
$49.68
N/A
Revenue Growth
61.35
15.10
52 Week Low
$10.45
$4.56
52 Week High
$54.70
$17.12

Technical Indicators

Market Signals
Indicator
IDR
EOLS
Relative Strength Index (RSI) 38.62 28.78
Support Level $37.40 $4.68
Resistance Level $41.28 $4.96
Average True Range (ATR) 4.22 0.30
MACD -1.15 -0.02
Stochastic Oscillator 1.88 10.19

Price Performance

Historical Comparison
IDR
EOLS

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: